Skip to main content

Market Overview

Palisade Bio-Newsoara Serine Protease Inhibitor Accelerates Return Of Bowel Function After GI Surgery

Palisade Bio-Newsoara Serine Protease Inhibitor Accelerates Return Of Bowel Function After GI Surgery

Palisade Bio Inc (NASDAQ: PALI) and co-development partner Newsoara have announced positive Phase 2 data LB1148 showing a statistically significant effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.

  • The 120-subject study showed a 1.1-day improvement in GI recovery in patients receiving LB1148 vs. placebo. 
  • The median time to return of bowel function was 2.77 days in patients treated with LB1148 and 3.83 days in those receiving placebo.
  • It demonstrated a 1.5-day faster recovery of bowel function compared to placebo (4.9 days).
  • LB1148 was well tolerated, with only 10.9% and 4.8% of patients in the LB1148 and placebo groups, respectively, experiencing a drug-related adverse event.
  • The most common drug-related adverse events were GI disorders (LB1148 4.7% vs. placebo 3.2%). No drug-related serious adverse events occurred in the trial.
  • LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. 
  • The release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions. 
  • Price Action: PALI shares are down 4.74% at $3.32 during the market session on the last check Thursday.

Related Articles (PALI)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at